Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 20, 2020 - Issue 4
Submit an article Journal homepage
1,170
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?

Takuro GotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA;James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USAView further author information
&
Hiroshi MiyamotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA;James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA;Department of Urology, University of Rochester Medical Center, Rochester, NY, USACorrespondence[email protected]
View further author information
Pages 229-231 | Received 31 Oct 2019, Accepted 05 Mar 2020, Published online: 24 Mar 2020

References

  • Howlader N, Krapcho AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD. based on November 2018 SEER data submission, posted to the SEER web site. 2019 April. Available from: https://seer.cancer.gov/csr/1975_2016/
  • Leiblich A. Recent developments in the search for urinary biomarkers in bladder cancer. Curr Urol Rep. 2017;18:100.
  • Lerner SP, Goh A. Novel endoscopic diagnosis of bladder cancer. Cancer. 2015;121:169–178.
  • Zehnder P, Studer UE, Skinner EC, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 2013;112:E51–E58.
  • Sathianathen NJ, Kalapara A, Frydenberg M, et al. Robotic assisted radical cystectomy vs open radical cystectomy: systematic review and meta-analysis. J Urol. 2019;201:715–720.
  • Wettstein MS, Rooprai JK, Pazhepurackel C, et al. Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: does the current quality of evidence justify definitive conclusions? PLoS One. 2019;14:e0216255.
  • Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:45–57.
  • Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–1073.
  • von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077.
  • Niglio SA, Jia R, Ji J, et al. Programmed Death-1 or programmed death Ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis. Eur Urol. 2019;76:782–789.
  • Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–348. .
  • Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525–1530.
  • Choudhury NJ, Campanile A, Antic T, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol. 2016;34:2165–2171.
  • Khaki AR, Li A, Diamantopoulos LN, et al. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors. Cancer. 2020;126:1208–1216.
  • Mizushima T, Tirador KA, Miyamoto H. Androgen receptor activation: A prospective therapeutic target for bladder cancer? Expert Opin Ther Targets. 2017;21:249–257.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.